Creative Biolabs is a global provider with the objective to develop new functional psychotropic drugs through our robust platform. We offer customers neurokinin (NK) receptor antagonist development services to promote the drug discovery of psychiatric disorders.
NK receptor is the main receptor for the tachykinin family of peptides. It belongs to the G protein-coupled receptors (GPCRs) family. Substance P and NK receptors are expressed in brain regions involved in stress, fear, and affective response (e.g., amygdala, hippocampus, hypothalamus, and frontal cortex). In fact, some studies show that substance P/NK receptor interaction plays an important role in the modulation of stress-related, affective, and/or anxious behavior.
NK Receptor Antagonist with Psychiatric Disorders
NK receptors are suggested to be novel targets for the treatment of psychoses or drug addiction. Specifically, the NK-1 receptors are involved in emotional responses to stress, suggesting that an alteration in the tachykinergic system may be the key to triggering pathogenesis such as depression. NK receptor antagonists may find utility in some psychiatric diseases, including schizophrenia, anxiety, and depressive disorders.
Fig.1 Signaling pathways activated by NK receptor. (Garcia-Recio, 2015)
Besides, NK receptor antagonists have shown preclinical activity in several paradigms of anxiety and depression. NK receptor antagonist using aprepitant has been tested as a novel antidepressant mechanism with major depressive disorder. For example, L-759274, a highly selective nonpeptide NK receptor antagonist, is an efficacious and well-tolerated antidepressant. In addition, another drug GR205171 can be used for the treatment to alleviate clinical symptoms in patients with a social anxiety disorder (SAD). Interestingly, NK receptor antagonists have also shown potential for the treatment of alcohol- and drug-related disorders that are often comorbid with mood and anxiety disorders.
NK Receptor Antagonist Development Services at Creative Biolabs
Many preclinical and clinical evidence indicates that NK receptor antagonists might represent a new approach to the treatment of schizophrenia and possibly other psychiatric disorders. Creative Biolabs provides NK receptor antagonist development services to satisfy your research requirements promptly. Our staff with technical expertise can meet various study endpoints to generate high-quality and reproducible results from your project requirements. We would be pleased to provide support for any of your questions and look forward to discussing your inquiry and finding the best solution for your needs.
Creative Biolabs is a dedicated psychotropic drug development provider that strives to provide the highest quality service. By partnering with Creative Biolabs, you gain access to target development support services that increase your research potential to be successful. If you want to know more about our services, please get in touch.
Reference
-
Garcia-Recio, S.; Gascón, P. Biological and pharmacological aspects of the NK1-receptor. BioMed research international. 2015. Distributed under Open Access license CC BY 3.0, without modification.
For Research Use Only.
